An observational study in Cardiogenic Shock and Acute Heart Failure (AHF), sponsored by University Heart Center Freiburg - Bad Krozingen. Recruiting at 4 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-29.
Sponsored by University Heart Center Freiburg - Bad Krozingen · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies in Shock, Cardiogenic with a site in Germany — 13 open to participants now, 13 under way, none of them phase 3. Shock, Cardiogenic · Germany.
Among the 36 studies in Shock, Cardiogenic with a site in Germany, this one is the 5th largest by planned enrollment of the 14 observational ones that give a count, is one of 3 that started in 2024, is one of 14 observational ones, reaches primary completion later than 4 of the 12 other live ones, and was the 33rd registered.
297 studies on the registry are indexed under Shock, Cardiogenic; 134 are open to participants now.
Browse Shock, Cardiogenic studies →13 of the 36 studies in Shock, Cardiogenic with a site in Germany are open now. Recruiting first, the newest first:
Leipzig Heart Science gGmbH · Sites in Germany
Ages 18–80
University Hospital of Cologne · Sites in Germany
Ages 18–77
4TEEN4 Pharmaceuticals GmbH · Sites in Germany, Armenia, Belgium and 6 more countries
Ages 18–80
Abiomed Inc. · Sites in Germany, Italy, Switzerland
Ages 18+
Universität Münster · Sites in Germany
Ages 18+
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 101 Shock, Cardiogenic studies recruiting now, 70 (69%) set no upper age limit and 9 (9%) stop at 75 or younger; 11 take children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 4 · Phase 3 1 · Phase 4 5
First in 2003; this study’s year is marked. 3 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 600 is above the median of 200 across 156 observational studies indexed under Shock, Cardiogenic.
Median enrollment 60 across the 22 interventional studies, 138 across the 14 observational. Of the 17 that completed or were terminated, 1 (6%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 36 have an industry lead sponsor. The 10 most frequent:
University Heart Center Freiburg - Bad Krozingen is the lead sponsor of 9 studies on the registry; 1 is open to participants now.
University Heart Center Freiburg - Bad Krozingen has 1 study filed under Shock, Cardiogenic — fewer than ten, so there is no comparison to draw.
4 of the studies in Shock, Cardiogenic with a site in Germany that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT068327224TEEN4 Pharmaceuticals GmbHA Phase 1b/2a Trial to Evaluate Invobenitug Also Known as Procizumab (PCZ; AK1967) in Critical Cardiovascular Care. | 2026-12-30 |
| NCT06308055Abiomed Inc.Abiomed Impella RT-DAQ - Observational Study | 2027-06-30 |
| NCT07515508University Heart Center Freiburg - Bad KrozingenMultimodal Phenotyping In Patients Referred With Acute Cardiac faiLurE | 2027-07-31 |
| NCT07687017Leipzig Heart Science gGmbHCRP Apheresis in Infarct-Related Cardiogenic Shock | 2027-09-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 36 studies in Shock, Cardiogenic with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this observational study is to learn whether information collected during routine hospital care, together with blood and urine samples, can help doctors better identify different types of cardiogenic shock and better predict outcomes in adults hospitalized with acute heart failure and cardiogenic shock. The main question is whether clinical findings, imaging results, and biomarkers, including sex-specific factors, are associated with the risk of death within 30 days. Participants will not receive an experimental treatment. Researchers will collect data from routine care, collect additional blood and urine samples for biobanking, and follow participants after hospital discharge
Consecutive adult patients hospitalized at participating study sites with acute heart failure and cardiogenic shock (SCAI stages B-E).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Mortality
Time frame: 30 days
Mortality
Time frame: 6 and 12 months
Rehospitalization for heart failure
Time frame: From hospital discharge until 12 months
Rehospitalization for cardiac reasons (non-elective)
Time frame: From hospital discharge until 12 months
Bleeding ≥ SHARC 3a
Time frame: Index hospitalization
Functional capacity (physical)
Six-minute walk test
Time frame: At 6 months follow up
Functional capacity (cognitive)
MOCA
Time frame: At 6 months follow up
Functional capacity
KCCQ
Time frame: At 6 months follow up
Quality of life measure
PHQ-2
Time frame: At 6 months follow up
Quality of life measure
EQ-5D-5L
Time frame: At 6 months follow up
Started Aug 2024 (actual). Primary completion is estimated for Jul 2027, 35 months after the start.
Of 79 non-industry observational studies under Shock, Cardiogenic, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 19. This study's planned 35 months is below that.
Counting every sponsor, half of 85 studies reached it within 45 months; a quarter within 24.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Heart Center Freiburg - Bad Krozingen